Neuropathic Pain

180

Pipeline Programs↗

29

Active Trials↗

78

Companies Involved↗

Neuropathic Pain is a highly competitive landscape with 180 programs across 78 companies. The most active players are Xalud Therapeutics, Inc., Sumitomo Pharma America, Inc., Johnson & Johnson. 39 therapies are approved with 36 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

37/100

Mech. Concentration

13/100

Completion Rate

77/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Xalud Therapeutics, Inc.

1 program

Sumitomo Pharma America, Inc.

1 program

Johnson & Johnson

1 program

Sanofi

4 programs

Biogen

3 programs

Bristol-Myers Squibb

2 programs

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

201 of 207 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 207 classified programs, each share of the total. Modality classified for 100% of 213 pipeline programs.

Analysis

Trial Status

251

clinical trials

Completed152 · 61%

Terminated38 · 15%

Unknown status25 · 10%

Recruiting19 · 8%

Not yet recruiting9 · 4%

Withdrawn6 · 2%

Other2 · 1%

Clinical Trials

Trial Activity

251 trials

Sleep and Neuropathic Pain - Intervention Study on Pregabalin

Recruiting·HHelsinki University Central Hospital·N/A·NCT06155916·40 enrolled

Crisugabalin for Radiotherapy-Related Neuropathic Pain

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06766916·172 enrolled

Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain

Recruiting·EEMS·Phase 3·NCT04666714·136 enrolled

Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain

Recruiting·VVA Office of Research and Development·Phase 2·NCT05351801·320 enrolled

Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain

Recruiting·—·Phase 4·NCT07451431·78 enrolled

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Recruiting·DDogwood Therapeutics Inc.·Phase 2·NCT06848348·200 enrolled

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

Recruiting·MMargaux M. Salas, PhD·Phase 4·NCT06414356·30 enrolled

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06518720·16 enrolled

Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities

Recruiting·—·Phase 2·NCT05623111·80 enrolled

Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial

Recruiting·UUnity Health Toronto·Phase 2·NCT07301632·40 enrolled

Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

Recruiting·CCentre Oscar Lambret·Phase 2·NCT06807164·123 enrolled

Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain

Recruiting·JJemincare·Phase 2·NCT06221241·220 enrolled

Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

Recruiting·UUnity Health Toronto·Phase 2·NCT06731335·30 enrolled

(2R,6R)-Hydroxynorketamine for the Treatment of Neuropathic Pain

Recruiting·RRush University Medical Center·Phase 1/2·NCT05864053·25 enrolled

Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

Recruiting· Haisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.·Phase 2·NCT06490484·90 enrolled

Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)